Technetium (99mTc) sulesomab
From Wikipedia, the free encyclopedia
(Redirected from Sulesomab)
|Target||NCA-90 (granulocyte cell antigen)|
|(what is this?)|
It is approved for the imaging of infections and inflammations in patients with suspected osteomyelitis, and is being investigated for other purposes like the detection of soft tissue infections.
- WHO Drug Information
- EMEA: Summary of product characteristics (LeukoScan)
- Quigley, A. M.; Gnanasegaran, G.; Buscombe, J. R.; Hilson, A. J. W. (2008). "Technetium-99m-Labelled Sulesomab (LeukoScan) in the Evaluation of Soft Tissue Infections". Medical Principles and Practice. 17 (6): 447–52. PMID 18836272. doi:10.1159/000151565.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|